checkAd
Exelixis Aktie
17,285
 
EUR
08:15:18 Tradegate
-0,97 %
-0,170 EUR
Geldkurs 12:25:38
17,270 EUR
290 Stk.
Briefkurs 12:25:38
17,605 EUR
284 Stk.

Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC). Following a …

Wertpapier:

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX) in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer …

Wertpapier:

Nachrichten

DatumTitel
17.09.21Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Business Wire (engl.) | Weitere Nachrichten
16.09.21Exelixis Announces CABOMETYX in Combination with OPDIVO Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
Business Wire (engl.) | Weitere Nachrichten
06.09.21Exelixis Statement on the Passing of Two Senior Executives
Business Wire (engl.) | Weitere Nachrichten
01.09.21Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
Business Wire (engl.) | Weitere Nachrichten
25.08.21Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
Business Wire (engl.) | Weitere Nachrichten
16.08.21Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
Business Wire (engl.) | Weitere Nachrichten
12.08.213 Top-Aktien, die dich im August (und darüber hinaus) reicher machen könnten
The Motley Fool | Kommentare
05.08.21Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Business Wire (engl.) | Weitere Nachrichten
05.08.21Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Business Wire (engl.) | Weitere Nachrichten
23.07.21Die besten Aktien, die du für 20 Euro kaufen kannst
The Motley Fool | Kommentare
22.07.21Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Business Wire (engl.) | Weitere Nachrichten
08.07.21Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
Business Wire (engl.) | Weitere Nachrichten
28.06.21Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
Business Wire (engl.) | Weitere Nachrichten
26.06.21Die besten Aktien, die man jetzt mit 100 Euro kaufen kann
The Motley Fool | Kommentare
18.06.21Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
Business Wire (engl.) | Weitere Nachrichten